Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer * Recurrent disease (any FIGO stage) * Not amenable to curative surgery or radiotherapy alone * Failed prior primary platinum-based therapy at least 6 months after therapy discontinuation * Measurable lesion by CT scan, MRI, chest x-ray, or sonography * Physical examination allowed for documenting lymph node and skin metastases * Physical gynecological examination allowed for well-defined palpable tumor lesions * Increase in CA 125 without any measurable tumor is not acceptable as indication of recurrence * No CNS metastases * No tumor of borderline malignancy PATIENT CHARACTERISTICS: Age * 18 to 65 Performance status * ECOG 0-2 Life expectancy * At least 24 weeks Hematopoietic * Neutrophil count at least 1,500/mm3 * Platelet count at least 100,000/mm3 Hepatic * Not specified Renal * Creatinine clearance at least 60 mL/min * No chronic or acute renal failure Cardiovascular * Cardiovascular function sufficient for hyperthermia treatment by stress-ECG * No cardiomyopathy with impaired ventricular function * No New York Heart Association class III or IV heart disease * No cardiac arrhythmias influencing LVEF and requiring medication * No myocardial infarction or angina pectoris within the past 6 months * No uncontrolled arterial hypertension Pulmonary * Pulmonary function sufficient for hyperthermia treatment by pulmonary function tests Other * No untreated endocrinological disease (e.g., hyperthyroidism or diabetes mellitus) * No other primary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer * No contraindication against hyperthermia treatment (e.g., photodermatosis, history of malignant hyperthermia, or claustrophobia) * No hypersensitivity to carboplatin, ifosfamide, or any other study medication * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * See Disease Characteristics * No concurrent cytotoxic or other antineoplastic therapy Endocrine therapy * Concurrent hormone replacement therapy allowed * Concurrent steroid antiemetics allowed Radiotherapy * See Disease Characteristics * At least 1 year since prior radiotherapy (tumoricidal dose) of the pelvis * Concurrent palliative local radiotherapy for painful (nonprogressive) existing lesion is allowed if other measurable sites are present * No concurrent radiotherapy to a second existing lesion Surgery * See Disease Characteristics Other * No prior form of hyperthermic therapy * At least 3 weeks since other medications as part of another clinical study * At least 3 weeks since prior investigational agents * At least 6 weeks since prior betablockers * No concurrent photosensitizing drugs * No concurrent betablockers * No other concurrent anticancer therapy